×
About 1,346 results
Fasting Triglycerides & Glucose Index: A Useful Screening Test for Assessing Insulin Resistance in Patients Diagnosed with Rheumatoid Arthritis & Systemic Lupus Erythematosus
https://dmsjournal.biomedcentral.com/articles/10.1186/s13098-019-0495-x
Diabetology & Metabolic Syndrome; Contreras-Haro B, et al

Nov 26th, 2019 - Insulin resistance (IR) is frequently observed in patients with rheumatoid arthritis (RA) or systemic lupus erythematosus (SLE). In clinical practice, IR assessment is limited to a low proportion of patients due to cost and equipment and technical expertise requirements. The surrogate index of triglycerides and glucose (TyG index) has been validated in non-rheumatic populations, showing adequat...

High-protein Diet is Bad for Kidney Health: Unleashing the Taboo
https://academic.oup.com/ndt/advance-article/doi/10.1093/ndt/gfz216/5614387
Nephrology Dialysis Transplantation; Kalantar-Zadeh K, et al

Nov 6th, 2019 - How often have you been told to eat more protein and less carbohydrates to stay healthy? This is not an emerging food culture but rather a prevailing dogma in our society. Physicians, dietitians and other health care professionals tell us constantly about the advantages of a high-protein diet (HPD), such as losing weight rapidly, burning calories, diminishing appetite, preventing obesity, manag...

Scientists design device for oral delivery of injections
https://www.nih.gov/news-events/nih-research-matters/scientists-design-device-oral-delivery-injections

Oct 28th, 2019 - Biologic drugs are complex medications produced from living organisms or their parts. They include vaccines and drugs to treat conditions like rheumatoid arthritis, psoriasis, and cancer. Some biologic drugs, like insulin, can only be delivered by injection. If taken by mouth, stomach acid would destroy the drug before it could take effect.

Pediatric Metabolic and Bariatric Surgery: Evidence, Barriers, and Best Practices
https://pediatrics.aappublications.org/content/early/2019/10/24/peds.2019-3223
Pediatrics Armstrong, S. et. al.

Oct 27th, 2019 - Severe obesity among youth is an “epidemic within an epidemic” and portends a shortened life expectancy for today’s children compared with those of their parents’ generation. Severe obesity has outpaced less severe forms of childhood obesity in prevalence, and it disproportionately affects adolescents. Emerging evidence has linked severe obesity to the development and progression of multiple co...

FDA approves Fiasp® for use in insulin infusion pumps for adults with type 1 or type 2 diabetes
https://www.novonordisk-us.com/media/news-releases.html?122974

Oct 21st, 2019 - Novo Nordisk today announced that the U.S. Food and Drug Administration (FDA) has expanded the label for Fiasp® (insulin aspart injection) 100 u/mL to include use in insulin infusion pumps for the improvement of glycemic control in adults with type 1 or type 2 diabetes.1 Fiasp®, a rapid-acting insulin, was approved by the FDA in 2017 for use by intravenous infusion under supervision by a health...

Genentech Announces FDA Approval of Xofluza (Baloxavir Marboxil) for People at High Risk of Developing Influenza-Related Complications
https://www.gene.com/media/press-releases/14817/2019-10-17/genentech-announces-fda-approval-of-xofl

Oct 16th, 2019 - Single-dose Xofluza is the first and only antiviral medicine indicated specifically for patients at high risk of developing serious complications from influenza (flu) The Centers for Disease Control and Prevention (CDC) defines people at high risk of serious flu complications as those who have conditions such as asthma, chronic lung disease, diabetes, heart disease, morbid obesity or adults ...

Weight change across adulthood in relation to all cause and cause specific mortality: prospective cohort study
https://www.bmj.com/content/367/bmj.l5584
BMJ Chen, C. et. al.

Oct 15th, 2019 - Objective To investigate the association between weight changes across adulthood and mortality. Design Prospective cohort study. Setting US National Health and Nutrition Examination Survey (NHANES) 1988-94 and 1999-2014. Participants 36 051 people aged 40 years or over with measured body weight and height at baseline and recalled weight at young adulthood (25 years old) and middle adul...

Association of Cardiovascular Disease With Premature Mortality in the United States
https://jamanetwork.com/journals/jamacardiology/fullarticle/2752889
JAMA Cardiology; Chen, Y. et. al.

Oct 15th, 2019 - Question How have the trends in premature mortality from cardiovascular disease (CVD) changed in the United States during 2000 to 2015 by demographics and county-level factors, including education, rurality, and the prevalence of smoking, obesity, and diabetes? Findings In this study, CVD mortality rates increased significantly among American Indian/Alaska Native individuals age 25 to 49 y...

Optimizing Postprandial Glucose Management in Adults With Insulin-Requiring Diabetes: Report and Recommendations
https://academic.oup.com/jes/article/3/10/1942/5581189
Journal of the Endocrine Society;

Oct 6th, 2019 - Faster-acting insulins, new noninsulin drug classes, more flexible insulin-delivery systems, and improved continuous glucose monitoring devices offer unprecedented opportunities to improve postprandial glucose (PPG) management and overall care for adults with insulin-treated diabetes. These developments led the Endocrine Society to convene a working panel of diabetes experts in December 2018 to...

Sleeping less than six hours and heart disease, stroke – deadly combo
https://newsroom.heart.org/news/sleeping-less-than-six-hours-and-heart-disease-stroke-deadly-combo

Oct 1st, 2019 - Middle-aged adults with high blood pressure, Type 2 diabetes, heart disease or stroke could be at increased risk for cancer and early death when sleeping less than 6 hours per day.

Preventive Cardiology as a Subspecialty of Cardiovascular Medicine
http://www.onlinejacc.org/content/74/15/1926?_ga=2.47888103.1317319445.1570642054-675541502.1568116402
Journal of the American College of Cardiology; Shapiro, M. et. al.

Oct 1st, 2019 - Although significant progress has been made to reduce the global burden of cardiovascular disease, efforts have focused primarily on treatment of manifest disease rather than on prevention of events. An enormous opportunity exists to transition focus from intervention to providing equal attention to prevention of cardiovascular disease. The nascent specialty of “preventive cardiology” is emergi...

U.S. FDA Approves INVOKANA® (canagliflozin) to Treat Diabetic Kidney Disease (DKD) and Reduce the Risk of Hospitalization for Heart Failure in Patients with Type 2 Diabetes (T2D) and DKD
https://www.janssen.com/us-fda-approves-invokana-canagliflozin-treat-diabetic-kidney-disease-dkd-and-reduce-risk

Sep 29th, 2019 - The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that the U.S. Food and Drug Administration (FDA) approved a new indication for INVOKANA® (canagliflozin) to reduce the risk of end-stage kidney disease (ESKD), worsening of kidney function, cardiovascular (CV) death, and hospitalization for heart failure in adults with type 2 diabetes and diabetic kidney disease (nephropa...

Pheochromocytoma and Paraganglioma Treatment (PDQ®)–Health Professional Version
https://www.cancer.gov/types/pheochromocytoma/hp/pheochromocytoma-treatment-pdq

Sep 24th, 2019 - Pheochromocytoma and paraganglioma treatment is usually surgery, however, preoperative medical preparation is critical. Palliative care for metastatic disease may include chemotherapy, radiation therapy, targeted therapy, and other modalities. Get detailed information in this clinician summary.

Screening and Management of the Hyperandrogenic Adolescent
https://www.acog.org/Clinical-Guidance-and-Publications/Committee-Opinions/Committee-on-Adolescent-Health-Care/Screening-and-Management-of-the-Hyperandrogenic-Adolescent

Sep 23rd, 2019 - Although androgen excess can manifest in many ways, the most common and recognizable symptoms are hirsutism and acne. Reports of hirsutism and acne should be taken seriously because of their possible association with medical disorders, their substantial effect on self-esteem and quality of life, and the potential for psychosocial morbidity. In patients with symptoms of androgen excess, the diff...

FDA approves Rybelsus® (semaglutide), the first GLP-1 analog treatment available in a pill for adults with type 2 diabetes
https://www.novonordisk-us.com/media/news-releases.html?122973

Sep 19th, 2019 - Novo Nordisk today announced that the U.S. Food and Drug Administration (FDA) has approved Rybelsus® (semaglutide) tablets 7 mg or 14 mg for adults with type 2 diabetes that along with diet and exercise may improve blood sugar (glucose).1 Rybelsus® is the first and only glucagon-like peptide-1 (GLP-1) analog in a pill and a new option for adults with type 2 diabetes who are not achieving their ...

Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction
https://www.nejm.org/doi/full/10.1056/NEJMoa1911303
The New England Journal of Medicine; McMurray, J. et. al.

Sep 18th, 2019 - BACKGROUND In patients with type 2 diabetes, inhibitors of sodium–glucose cotransporter 2 (SGLT2) reduce the risk of a first hospitalization for heart failure, possibly through glucose-independent mechanisms. More data are needed regarding the effects of SGLT2 inhibitors in patients with established heart failure and a reduced ejection fraction, regardless of the presence or absence of type 2 ...

Lipoprotein(a): The Next Promising CVD Risk Assessment Tool and Prevention Target Among the High-risk Population
https://www.acc.org/latest-in-cardiology/articles/2019/09/17/15/02/lipoprotein-a

Sep 17th, 2019 - After low density lipoprotein cholesterol (LDL-C) has been targeted to reduce cardiovascular disease (CVD) risk, other novel lipid biomarkers have become the center of attention of investigation, and on-going clinical trials are targeting these lipid markers trying to lower the so-called "residual CVD risk" in addition to conventional lipid-lowering therapy. Among them, serum lipoprotein(a) [Lp...

Efficacy and safety of once-weekly semaglutide versus daily canagliflozin as add-on to metformin in patients with type 2 diabetes (SUSTAIN 8): a double-blind, phase 3b, randomised controlled trial
https://www.thelancet.com/journals/landia/article/PIIS2213-8587(19)30311-0/fulltext
The Lancet Diabetes & Endocrinology; Lingvay, I. et. al.

Sep 16th, 2019 - Existing guidelines for management of type 2 diabetes recommend a patient-centred approach to guide the choice of pharmacological agents. Although glucagon-like peptide-1 (GLP-1) receptor agonists and sodium–glucose cotransporter-2 (SGLT2) inhibitors are increasingly used as second-line agents, direct comparisons between these treatments are insufficient. In the SUSTAIN 8 trial, we compared the...

New CDC Obesity Prevalence Maps: Nine states report adult obesity at or above 35 percent
https://www.cdc.gov/media/releases/2019/s0912-obesity-prevalence-maps.html

Sep 11th, 2019 - In 2018, nine states reported an adult obesity prevalence at or above 35 percent: Alabama, Arkansas, Iowa, Kentucky, Louisiana, Mississippi, Missouri, North Dakota, and West Virginia. This comes from the new obesity prevalence maps released today by the Centers for Disease Control and Prevention.

Xeris Pharmaceuticals Receives U.S. Fda Approval For Gvoke™ (Glucagon), The First Ready-to-use Stable Liquid Glucagon For Severe Hypoglycemia
https://xerispharma.gcs-web.com/news-releases/news-release-details/xeris-pharmaceuticals-receives-us-fda-approval-gvoketm-glucagon

Sep 9th, 2019 - Xeris Pharmaceuticals, Inc. (Nasdaq: XERS), a specialty pharmaceutical company leveraging its novel technology platforms to develop and commercialize ready-to-use injectable and infusible drug formulations, announced today that it has received regulatory approval from the U.S. Food and Drug Administration (FDA) for GVOKE™ (glucagon) injection, its ready-to-use, room-temperature stable liquid gl...